What are the optimal medication choices for managing generalized anxiety disorder, obsessive‑compulsive disorder, and anorexia nervosa?

Optimal Medication Strategy for Anxiety, OCD, and Anorexia

For a patient presenting with all three conditions—generalized anxiety disorder, obsessive-compulsive disorder, and anorexia nervosa—initiate fluoxetine 60 mg daily as the single agent that addresses both OCD and anxiety, while prioritizing eating disorder-focused psychotherapy as the primary treatment for anorexia nervosa, since no medication has proven efficacy for anorexia itself. 1

Rationale for Fluoxetine as First-Line Agent

Fluoxetine 60 mg daily is the optimal choice because it is the only SSRI with FDA approval for an eating disorder (bulimia nervosa), has the strongest evidence base for OCD when dosed at 60 mg, and effectively treats generalized anxiety disorder. 2, 1

• The 60 mg dose is critical—OCD requires higher-than-typical antidepressant dosing, and lower doses will fail to adequately control obsessive-compulsive symptoms 3, 1
• SSRIs are first-line pharmacotherapy for both GAD and OCD, with fluoxetine, escitalopram, sertraline, and paroxetine all demonstrating efficacy 4, 5
• For anorexia nervosa specifically, SSRIs have minimal evidence for weight restoration or acute symptom improvement, but may help prevent relapse once weight is restored and can address comorbid anxiety/OCD symptoms 2, 6

Critical Caveat: Psychotherapy is Primary for Anorexia

The American Psychiatric Association explicitly recommends against relying on medication as primary treatment for anorexia nervosa—eating disorder-focused psychotherapy with weight restoration is the cornerstone of treatment 2

• For adults with anorexia nervosa, initiate eating disorder-focused psychotherapy that includes normalizing eating behaviors, restoring weight, and addressing fear of weight gain and body image disturbance 2
• For adolescents and emerging adults with involved caregivers, family-based treatment is the recommended approach 2
• Concurrent exposure and response prevention (ERP) therapy should be added to specifically target OCD symptoms 1, 4

Baseline Monitoring Requirements

Before initiating fluoxetine, obtain an ECG (mandatory in restrictive eating disorders and purging behaviors), comprehensive metabolic panel, CBC, liver and renal function tests, and orthostatic vital signs. 2, 1

• ECG monitoring is essential because patients with anorexia nervosa are at risk for QTc prolongation, especially with purging behaviors or electrolyte abnormalities 2
• Track weight, vital signs, and orthostatic changes throughout treatment 2, 1

Treatment Timeline and Response Assessment

Evaluate treatment response at 8–12 weeks, though early improvement may appear at 2–4 weeks. 1, 7

• If partial response at 8–12 weeks, continue fluoxetine and optimize the dose 1
• If minimal or no response after 8–12 weeks at maximum tolerated dose, switch to another SSRI (sertraline, paroxetine, fluvoxamine, escitalopram) at the upper end of the dosing range 3, 1
• Alternatively, switch to clomipramine, which has comparable efficacy to SSRIs for OCD but requires cardiac monitoring due to QTc prolongation risk 3, 1, 7

Second-Line and Augmentation Strategies

If two adequate SSRI trials (including fluoxetine) fail after 8–12 weeks each at maximum tolerated doses, augment with an atypical antipsychotic such as risperidone or aripiprazole. 3, 1, 7

• Clomipramine is an alternative second-line agent after SSRI failure, with efficacy comparable to SSRIs but lower tolerability due to anticholinergic effects 3, 1
• Atypical antipsychotics are the established augmentation strategy for treatment-resistant OCD 3, 1, 7
• In patients with anorexia nervosa, antipsychotic augmentation requires extremely careful metabolic and weight monitoring due to risk of further weight loss and metabolic complications 1

Maintenance and Relapse Prevention

Continue pharmacotherapy for at least 12–24 months after symptom remission due to the high relapse risk in OCD. 1

• SSRIs may aid in relapse prevention and improvement of psychiatric symptoms in weight-restored anorexic patients, though they lack efficacy during acute malnutrition 6, 8
• Fluoxetine, citalopram, sertraline, or mirtazapine may be used adjunctively for relapse prevention and treatment of residual depressive, anxiety, or obsessive-compulsive symptoms that persist despite nutritional rehabilitation 6

Medications to Avoid

Do not use tricyclic antidepressants (except clomipramine for OCD), monoamine oxidase inhibitors, or bupropion in patients with eating disorders. 6

• Bupropion is contraindicated due to increased seizure risk in patients with eating disorders 6
• Tricyclic antidepressants and MAOIs carry unacceptable safety profiles in this population 6

Integrated Treatment Algorithm

1. Initiate fluoxetine 60 mg daily 1
2. Start eating disorder-focused psychotherapy concurrently (family-based for adolescents/young adults, individual CBT for adults) 2, 1
3. Add exposure and response prevention therapy for OCD symptoms 1, 4
4. Reassess at 8–12 weeks: continue if partial response; switch to another SSRI or clomipramine if minimal response 1
5. If inadequate after second pharmacologic agent, augment with atypical antipsychotic 1, 7
6. Maintain for 12–24 months after remission 1